Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | RXRB | P28702 | 2/20 | 0.43 |
| ▸ | RXRG | P48443 | 2/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 8/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9470568 | 0.84 | DRD2 (0.39) | TDP1L3MBTL1 | |
| SCHEMBL12646855 | 0.82 | KDM4E (0.42) | PTPN1 | |
| SCHEMBL1637318 | 0.81 | RXRA (0.46) | RXRARXRBRXRGMAPTMAPK1 | |
| SCHEMBL6640539 | 0.80 | MAPT (0.55) | RXRARXRBRXRGPTGER1PTGER4 | |
| SCHEMBL16072722 | 0.79 | KCNA3 (0.46) | RXRARXRBRXRGPTGER1MAPT | |
| SCHEMBL21811791 | 0.78 | PTGS2 (0.39) | PTPN1 | |
| SCHEMBL367003 | 0.78 | DRD2 (0.42) | MAPK1TDP1L3MBTL1 | |
| SCHEMBL591400 | 0.78 | MAPT (0.46) | RXRARXRBRXRGMAPTMAPK1 | |
| SCHEMBL30718956 | 0.76 | MAPT (0.46) | RXRARXRBRXRGPTGER1MAPT | |
| SCHEMBL30705191 | 0.76 | DRD2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2493932-A2 | CATALYST COMPOUNDS AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056423-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | ALOX12, THEM6, ALOX15 | RXRA 1872/4885RXRB 2650/4885RXRG 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.